Markets

Will the breakthrough pancreatic cancer therapy advance to human clinical trials by the end of 2026?

Yes0%No0%
Loading...

About this market

This market resolves to Yes if the newly developed pancreatic cancer therapy, which showed long-lasting tumor regression in mice, advances to human clinical trials by December 31, 2026. Evidence of advancement is considered from reputable sources such as official announcements from involved research institutions or clinical trial registries.

Rules

  • Market closes at 12/31/2026.
  • Logic weighted resolution applies.